

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/013960 A1

(51) International Patent Classification⁷: **A61K 31/18**,
31/137, 47/14

[KR/KR]; 1312-904, Mokdong Apt., Shinjeong 6-dong,
Yangcheon-gu, Seoul 158-773 (KR).

(21) International Application Number:
PCT/KR2004/001421

(74) Agent: **KWON, HYUK-CHEOL**; 226 Doosan We've
Centium, 823-26 Yeoksam-dong, Gangnam-gu, Seoul
135-080 (KR).

(22) International Filing Date: 15 June 2004 (15.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2003-0055579 12 August 2003 (12.08.2003) KR
10-2004-0023668 7 April 2004 (07.04.2004) KR

(71) Applicant (for all designated States except US):
KYUNG DONG PHARM. CO., LTD. [KR/KR]; 535-3,
Daeyang-ri, Yanggam-myun, Whaseong 445-931 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LEE, BY-
OUNG-SUK** [KR/KR]; 1-1106, Imgwang Apt., 1015
Bangbae 3-dong, Seocho-gu, Seoul 137-755 (KR). **LEE, AH-RAM** [KR/KR]; 4-102 Kumho Apt., Seon-
hak-dong, Yeonsu-gu, Incheon 406-704 (KR). **PARK,
JONG-SIK** [KR/KR]; 323-701 Olympic-seonsuchon Apt.,
89 Bangi-dong, Songpa-gu, Seoul 138-788 (KR). **KIM,
EUN-JU** [KR/KR]; 202-ho, 243-8, Seryoo 1-dong, Gwon-
seon-gu, Suwon 441-867 (KR). **GIL, HYUNG-JOON**

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PREPARING METHOD FOR CONTROLLED RELEASED TYPE TABLET TAMSULOSIN HCL AND THE TABLET THEREOF

(57) Abstract: The present invention relates to a simple and effective method for preparing a tamsulosin HCl sustained-release tablet and a tamsulosin HCl sustained-release tablet produced thereby. The method comprises the steps of: dissolving tamsulosin HCl as an active ingredient in an organic solvent; dissolving the tamsulosin HCl solution in hydroxypropylmethylcellulose phthalate to prepare a binder solution; and kneading the binder solution with a hydroxypropylmethylcellulose phthalate/glyceryl dibhenate mixture as an excipient and allows tamsulosin HCl to be released at uniformly controlled amounts in a sustained-release manner in vivo by controlling drug release rate according to different pH environments in vivo, so that it shows improved bioavailability and minimized side effects.

WO 2005/013960 A1